D. R. J. SINGER, M.R.C.P.; T. J. FALLON, M.B., Ch.B.; W. E. SCHULENBURG, F.R.C.S.; G. WILLIAMS, F.R.C.S.; J. COHEN, M.SC., M.R.C.P.
To the editor: We read with interest the three reports (1-3) of treatment with dihydroxy-propoxymethylguanine (DHPG) in 15 immunocompromised patients with cytomegalovirus infection. It was notable that in 5 patients with retinitis, relapse occurred as early as 4 weeks after the end of DHPG infusion and that daily maintenance treatment was required to sustain remission. Foscarnet (4) is a virostatic agent of importance in the treatment of cytomegalovirus infections after renal and bone marrow transplantation (5). We have recently used foscarnet to treat a patient with the acquired immunodeficiency syndrome and cytomegalovirus retinitis.
A white heterosexual man aged 54 years
D. R. J. SINGER, T. J. FALLON, W. E. SCHULENBURG, G. WILLIAMS, J. COHEN. Foscarnet for Cytomegalovirus Retinitis. Ann Intern Med. 1985;103:962. doi: 10.7326/0003-4819-103-6-962_2
Download citation file:
Published: Ann Intern Med. 1985;103(6_Part_1):962.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use